Denovo Biopharma

San Diego, United States Founded: 2013 • Age: 13 yrs
Genomic biomarker discovery platform is developed for drug personalization.

About Denovo Biopharma

Denovo Biopharma is a Healthcare company based in San Diego (United States) founded in 2013. Genomic biomarker discovery platform is developed for drug personalization. Denovo Biopharma has raised $171.82 million across 4 funding rounds from investors including CICC, Qcc and CITIC. The company has 42 employees. Its focus areas include Life Sciences, Genomics, Genomics Research and Biomarker Discovery. Its legal entity is DENOVO BIOPHARMA LLC. Its competitors include Metabolon, Avidity Biosciences and Sutro Biopharma; 3 of its 3 listed competitors have raised funding.

Company details

Denovo Biopharma was founded in 2013 and is based in San Diego, United States. The company operates in the biopharmaceutical sector, where a genomic biomarker discovery platform is utilized to identify biomarkers for personalized drug development. This approach is applied across multiple therapeutic areas, including oncology, metabolic disorders, cardiology, immunology, and neurology, supporting targeted therapies in clinical applications.

  • Headquarters San Diego, United States
  • Employees 42
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website denovobiopharma.com
  • Social LinkedIn
  • Legal Name Denovo Biopharma Llc
Key Metrics
  • Total Equity Funding
    $171.82M (USD)

    in 4 rounds

  • Latest Funding Round
    $45.9M (USD), Series D

    Dec 2020

  • Investors
    CICC

    & 13 more

  • Employee Count
    42

Funding Insights of Denovo Biopharma

Denovo Biopharma has successfully raised a total of $171.82M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $45.9 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $171.82M
  • Total Rounds 4
  • Last Round Series D β€” $45.9M
  • Investors Count 14

All 4 funding rounds of Denovo Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2020$45.9MSeries D–Yingke Capital
–
Jun 2020$83.32MSeries C–CICC
Oct 2019$42.6MSeries B–Jiuyou Fund, Share Capital
–
Jul 2015Series A–Zhejiang Xianju Pharmaceutical, Guangzhou Yuexiu Industrial Investment Fund Management
–
Valuation history

14 investors in total: 14 institutional.

Investors in Denovo Biopharma

Denovo Biopharma has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include CICC, Qcc and CITIC.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
A venture capital firm based in Shenzhen, China, is operated.
sharecapital.cnShenzhen, China
Investment bank & PE fund focused on multiple sectors
jiuyoucapital.com.cn
A venture capital firm focused on life sciences investments.
sangelvc.comShenzhen, China
gzvcm.com
Yuexiu Capital is engaged in financial services and asset management.
yuexiufund.comGuangzhou, China
Private equity investments in China are handled by Goldstone Investment.
goldstone-investment.comBeijing, China
Operates as an investment advisory firm providing expert guidance.
2010yingkepe.comFuzhou, China
Diversified asset management and corporate advisory services are provided.
1995cicc.comBeijing, China
Provider of investment, wealth & asset management services
1995cs.ecitic.comBeijing, China
Jiuyou Fund is engaged in investment management and financial services.
jiuyoufund.comShanghai, China
Premium access

Investor details for Denovo Biopharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Denovo Biopharma

20 people are tracked at Denovo Biopharma (13 in leadership, 6 in board & advisors, 1 in team); the tracked headcount is 42.

NameRoleGroup
Sina Burrell
Head of Quality AssuranceLeadership
Carrie Chen
Chief Financial OfficerLeadership
Martin Mumenthaler
Sr. Director, Clinical SciencesLeadership
Michael Haller
Chief Business Officer And Head Of US FinanceLeadership
Wen Luo
CEO & CSOLeadership
Xiangming Fang
Chief Operating OfficerLeadership
Yu Sun
Director Of Finance And AccountingLeadership
Xiao-Xiong Lu
Chief Technical OfficerLeadership
Sudhir Borgonha, MD
Vice President, Clinical Development (Oncology)Leadership
Holly Huang, PhD, MPH
Vice President and Head of BiometricsLeadership
Julie Doostzadeh
Executive Director of Clinical OperationsLeadership
Crystal Chen
Vp, CNS Clinical DevelopmentLeadership
Anupam Agarwal, MD, MPH
Senior Vice President, Global Head of Drug Safety & PVLeadership
K. Peter Hirth
AdvisorsBoard & advisors
Steven Leventer
AdvisorBoard & advisors
John M. Davis
AdvisorBoard & advisors
Jeremy Barton
AdvisorBoard & advisors
Robert Alexander
AdvisorBoard & advisors
W. K. Alfred Yung
AdvisorBoard & advisors
Larry D. Alphs
SVP, CNS Clinical DevelopmentTeam
Premium access

Complete people profiles for Denovo Biopharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Denovo Biopharma

3 dated milestones of Denovo Biopharma across 7 years, from founding to its latest funding, stage changes and deals.

  1. Founded Denovo Biopharma is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Series D, of $45.9M.

Competitors of Denovo Biopharma

Denovo Biopharma has 3 listed competitors in our database, 3 of them funded. They include Metabolon, Avidity Biosciences and Sutro Biopharma.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
metabolon.com2000Morrisville, United States$165.87M189
Solutions for biomarker discovery and diagnostic testing are provided.
aviditybiosciences.com2012San Diego, United States$142.54M253
Antibody-siRNA complexes are developed for cancer treatment.
sutrobio.com2003United States$171.85M235
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
Premium access

Detailed competitors of Denovo Biopharma

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Denovo Biopharma

The website of Denovo Biopharma (denovobiopharma.com) receives about 1.7K visits a month.

  • Monthly visits
    1.7K

    ▲ 16% vs previous month

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Denovo Biopharma (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Denovo Biopharma

Premium access

Complete news archive for Denovo Biopharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Denovo Biopharma

Denovo Biopharma was founded in 2013 and raised its 1st funding round 2 years after it was founded.

Denovo Biopharma is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Denovo Biopharma is a funded company, having raised a total of $171.82M across 4 funding rounds to date.

Denovo Biopharma has 42 employees.

Denovo Biopharma was founded in 2013 and is based in San Diego, United States. The company operates in the biopharmaceutical sector, where a genomic biomarker discovery platform is utilized to identify biomarkers for personalized drug development. This approach is applied across multiple therapeutic areas, including oncology, metabolic disorders, cardiology, immunology, and neurology, supporting targeted therapies in clinical applications.

Denovo Biopharma's top competitors include Sutro Biopharma, Avidity Biosciences and Metabolon.

Denovo Biopharma has 14 investors. Key investors include CICC, Qcc, CITIC, Zhejiang Xianju Pharmaceutical, and Yingke Capital.

Denovo Biopharma operates through Denovo Biopharma Llc.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available